TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a securities fraud lawsuit against MoonLake Immunotherapeutics for allegedly misleading investors about its drug candidate sonelokimab, which resulted in a significant stock price drop after disappointing Phase 3 trial results.

Insights
DZZ   neutral

Mentioned as a previous employer of Zastre & Co's founding team, with no direct positive or negative implications


MLTX   negative

Company allegedly made false statements about drug candidate, misled investors about treatment superiority, and experienced a 90% stock value loss after revealing poor clinical trial results